Outcomes
INFLAMMATION, GCA, CONCOMITANT DISEASE, RELAPSE
The composite outcome “therapeutical benefit” was reached in subjects without suspicion of clinical activity and with the absence of new GCA symptoms (suspected to be related to GCA) and decreasing or stable CRP combined with decreasing daily prednisolone dose at 3 and 6 months post-initiation of JAKi.In addition, 6 months after the start of JAKi, two rheumatologists independently re-evaluated if the inflammatory activity at the initiation of JAKi was attributed to GCA or if other concomitant diseases had caused the inflammation. In the latter case, the patient was withdrawn from the study.Relapse of GCA was defined as suspicion of clinical activity based on relevant symptoms and increasing CRP (in the absence of other concomitant diseases) leading to an increase of daily prednisolone dose.